J. Hasford

发表

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol

E. Bonifacio, J. Todd, A. Ziegler, 2021, BMJ Open.

Four reasons why too many informed consents to clinical research are invalid: a critical analysis of current practices

Anne Wisgalla, J. Hasford, 2022, BMJ Open.

Assessing the Safety of Drugs in Pregnancy

C. Irl, Joerg Hasford, J. Hasford, 2000, Drug safety.

Challenges and proposed solutions in making clinical research on COVID-19 ethical: a status quo analysis across German research ethics committees

D. Strech, A. Sierawska, Anne Wisgalla, 2020, BMC Medical Ethics.

Compliance and the Benefit/Risk Relationship of Antihypertensive Treatment

J. Hasford, J. Hasford, 1992, Journal of cardiovascular pharmacology.

Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study

E. Bonifacio, A. Beyerlein, A. Ziegler, 2018, Molecular metabolism.

Evaluating quality-of-life measures for clinical trials in Germany.

J. Hasford, M. Bullinger, M. Bullinger, 1991, Controlled clinical trials.

Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: Comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid

T. Sauerbruch, G. Paumgartner, M. Sackmann, 1991, Hepatology.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

J. Hasford, M. Baccarani, R. Hehlmann, 1998, Journal of the National Cancer Institute.

Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions.

B Müller-Oerlinghausen, J Hasford, J. Hasford, 2002, Journal of clinical epidemiology.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

R. Schlenk, A. Ganser, K. Götze, 2012, Leukemia.

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

H. Heimpel, D. Hossfeld, R. Hehlmann, 1994, Blood.

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

M. Baccarani, G. Ossenkoppele, R. Hehlmann, 2016, Leukemia.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

K. Spiekermann, M. Pfreundschuh, L. Kanz, 2015, Leukemia.

The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies.

J Hasford, J. Hasford, A. Meining, 2005, Endoscopy.

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

M. Baccarani, H. Kluin-Nelemans, G. Rosti, 2001, Blood.

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

H. Heimpel, D. Hossfeld, R. Hehlmann, 1993, Blood.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

A. Glasmacher, P. Fenaux, A. List, 2012, Leukemia.

A Prospective Randomized Comparison of Unsedated Ultrathin Versus Standard Esophagogastroduodenoscopy in Routine Outpatient Gastroenterology Practice: Does It Work Better through the Nose?

J. Hasford, B. Birkner, N. Fritz, 2003, Endoscopy.

Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion.

J. Hasford, K. Theisen, D. Fassbender, 1990, The American journal of cardiology.

Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.

J Hasford, S. Schneeweiss, J. Hasford, 1997, Pharmacoepidemiology and drug safety.

Persistence with asthma treatment is low in Germany especially for controller medication – a population based study of 483 051 patients

J. Virchow, J. Virchow, J. Hasford, 2010, Allergy.

Excess mortality in patients with asthma on long-acting β2-agonists

J. Virchow, J. Hasford, J. Virchow, 2006, European Respiratory Journal.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

T. Brümmendorf, K. Spiekermann, M. Pfreundschuh, 2017, Leukemia.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

M. Höglund, M. Baccarani, K. Indrák, 2017, Leukemia.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

M. Baccarani, R. Clark, K. Indrák, 2015, Leukemia.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

H. Einsele, J. Hasford, K. Spiekermann, 2012, Leukemia.

Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.

H. Heimpel, J. Hasford, M. Horowitz, 1998, Blood.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

H. Einsele, J. Hasford, K. Spiekermann, 2014, Leukemia.

Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

M. Baccarani, H. Kluin-Nelemans, F. Mahon, 2003, Seminars in hematology (Print).

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

H. Heimpel, R. Hehlmann, A. Hochhaus, 2009, Leukemia.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

R. Hehlmann, A. Hochhaus, J. Hasford, 2011, Leukemia.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.

N. Schmitz, H. Heimpel, M. Griesshammer, 1996, Bone marrow transplantation.

Abstract

K. Laczika, C. Marosi, D. Fuchs, 1984, Veterinary Record.

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

M. González-Díaz, N. Puig, N. Thielen, 2015, Leukemia.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

J. Hasford, T. Brümmendorf, D. Hossfeld, 2016, Leukemia.

Regional reporting of adverse drug reactions: a new computer‐based network

M. Göttler, Walter J. Swoboda, J. Hasford, 1999, Pharmacoepidemiology and drug safety.

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

W. Siegert, H. Heimpel, A. Zander, 1999 .

Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death

M. Lauseker, V. Hoffmann, M. Pfirrmann, 2021, Hematologic Malignancies.